Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VLP Peanut · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A - Group A1 | EXPERIMENTAL | 4 parallel cohorts (1-4) of adult healthy subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut. |
| Part A - Group A2 | EXPERIMENTAL | Adult peanut allergic subjects, will undergo skin prick tests with ascending concentrations of VLP Peanut. |
| Part B - Cohorts 1-4 | EXPERIMENTAL | 4 parallel cohorts (1-4) of peanut allergic subjects. Each cohort will receive 6 ascending subcutaneous administrations of VLP Peanut. |
| Name | Type | Description |
|---|---|---|
| VLP Peanut | BIOLOGICAL | solution for subcutaneous administration |
| Placebo | BIOLOGICAL | solution for subcutaneous administration |
Part A Main Inclusion Criteria: 1. Capable of giving signed informed consent. 2. Subject who has a signed and dated Informed Consent Form (ICF). 3. Subject must be 18 to 50 years inclusive, at the time of signing the ICF. 4. Male or female. 5. Female subjects who are not of childbearing potential (...
VLP Peanut is an investigational monoclonal antibody being developed for the treatment of peanut allergy. It is currently in Phase 1 clinical development and is not yet approved by the FDA. The drug is being studied in both healthy volunteers and individuals with peanut allergy.
VLP Peanut is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical trials to evaluate the safety and efficacy of VLP Peanut for peanut allergy.
VLP Peanut is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is actively enrolling participants, though recruitment is not currently open.
VLP Peanut is being studied in a Phase 1 clinical trial registered as NCT05476497, titled 'Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects.' The trial is active but not recruiting, with an enrollment of 46 participants in the United States.
Yes, VLP Peanut is a monoclonal antibody. It is being developed as an investigational treatment for peanut allergy and is currently in Phase 1 clinical trials. The drug is being evaluated in a controlled, randomized, double-blind study.